{
    "nctId": "NCT03946202",
    "briefTitle": "KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer",
    "officialTitle": "Randomised Phase II Trial Testing Efficacy of Intra-tumoural Hydrogen Peroxide as a Radiation Sensitiser in Patients With Locally Advanced/Recurrent Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 184,
    "primaryOutcomeMeasure": "Complete tumour response based on best response assessed by contrast enhanced MRI according to criteria outlined in Section 3.2.1 of the trial protocol, performed up to and including 12 months post radiotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient age 18 years and over\n* Primary locally advanced breast cancer, or locally recurrent breast cancer with/without metastases (metastases, if present, should be stable or oligometastatic)\n* Radical/high dose palliative radiotherapy required for lifetime control of local morbidities\n* Patient physically and mentally fit for radical/high dose palliative radiotherapy\n* Target tumour accessible for intra-tumoural injection\n* Patient suitable/compliant with MR protocol\n* At least one tumour diameter \u226530 mm and \u2264150 mm measurable by ultrasound or MR imaging\n* Patients with predicted life expectancy of 12 months or more\n* Negative pregnancy test before start of radiotherapy in women of child bearing potential and an ability/willingness to protect against pregnancy from consent and for 3 months post-radiotherapy\n* Patient offers written informed consent\n\nExclusion Criteria:\n\n* Prior radiotherapy to the target area\n* Maximum diameter of target tumour \\<30 mm or \\>150mm measurable by ultrasound or MR\n* Anatomical location and/or extent of disease difficult to access for safe intra-tumoural drug injections, for example by virtue of contiguous major blood vessels and/or brachial plexus\n* Concomitant chemotherapy or biological therapy except Herceptin, Pertuzumab and Denosumab (all endocrine therapies and bisphosphonates are allowed concomitantly; other cytotoxics and biological therapies apart from those mentioned above should be stopped 3 weeks prior to RT)\n* Pregnancy or nursing\n* Hypersensitivity to any of the KORTUC ingredients",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}